Adaptimmune Therapeutics Earlier Reported Q2 EPS $(0.05) Beats $(0.25) Estimate, Sales $5.54M Miss $6.00M Estimate
Adaptimmune Therapeutics Earlier Reported Q2 EPS $(0.05) Beats $(0.25) Estimate, Sales $5.54M Miss $6.00M Estimate
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.25) by 80 percent. This is a 79.17 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $5.54 million which missed the analyst consensus estimate of $6.00 million by 7.70 percent. This is a 78.93 percent increase over sales of $3.10 million the same period last year.
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.25) by 80 percent. This is a 79.17 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $5.54 million which missed the analyst consensus estimate of $6.00 million by 7.70 percent. This is a 78.93 percent increase over sales of $3.10 million the same period last year.
自適應免疫治療公司(納斯達克市場代碼:ADAP)公佈季度虧損為每股0.05美元,比分析師普遍預期的0.25美元高出80%。這比去年同期每股虧損0.24美元增加了79.17%。該公司公佈的季度銷售額為554萬美元,低於分析師一致預期的600萬美元,降幅為7.70%。這比去年同期310萬美元的銷售額增長了78.93%。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧